
CVRx (CVRX) Stock Forecast & Price Target
CVRx (CVRX) Analyst Ratings
Bulls say
CVRx is a commercial-stage medical device company that is expected to experience continued growth due to its unique Baroreflex Activation Therapy, growing salesforce productivity, and potential approval for a new indication in treating HFrEF. The company's strong position in the U.S. market, recent reimbursement approvals, and ongoing clinical trials should continue to drive revenue growth in the near and long-term. While there are risks associated with the company's dependence on a single product and limited long-term clinical data, the company's current financial performance and forward-looking guidance suggest a positive outlook for investors.
Bears say
CVRx is a commercial-stage medical device company with concentrated revenue in the US, primarily from a single product,Barostim Neo. Despite recent growth in revenue and active accounts, CVRx's concentrated revenue, limited sales experience and uncertainty surrounding reimbursement and long-term clinical data lead to a negative outlook. Additionally, the company expects to incur significant losses and potential dilution, which may deter investors.
This aggregate rating is based on analysts' research of CVRx and is not a guaranteed prediction by Public.com or investment advice.
CVRx (CVRX) Analyst Forecast & Price Prediction
Start investing in CVRx (CVRX)
Order type
Buy in
Order amount
Est. shares
0 shares